Search is Powered by Google
Pharma Industry / Biotech Industry News

Political Atmosphere Prompts Scrutiny Of Pharmaceutical Industry

Main Category: Pharma Industry / Biotech Industry
Article Date: 24 Jan 2008 - 12:00 PDT

email icon email to a friend   printer icon printer friendly   write icon view / write opinions   rate icon rate article
Current Article Ratings:

Patient / Public:not yet rated

Health Professional:3 stars

3 (1 votes)

Article Opinions: 0 posts

With "weak new product pipelines" and "sagging stock values," drug companies are "increasingly relying on the government for revenue," though those prospects could be dim as some congressional lawmakers are "gearing up investigations and hearings that could shed a harsh light" on the industry's business practices, the Wall Street Journal reports. According to the Journal, the Medicare prescription drug benefit "increased the portion of retail prescription drug purchases paid for by government sources to 34% last year, from 28% in 2005."

However, the "growing role" of government in the drug industry's business could make pharmaceutical companies "more vulnerable to shifting political winds," the Journal reports. For instance, the House Energy and Commerce Committee is looking into the marketing of several drugs, including Vytorin, Lipitor, Procrit and Aranesp. In addition to scrutiny on Capitol Hill, many of the presidential candidates -- including the three Democratic front-runners and Sen. John McCain (R-Ariz.) -- support importing less-expensive drugs from Canada, while the Democratic candidates also support allowing Medicare to negotiate drug prices with the industry.

Drug Industry Response
Pharmaceutical Research and Manufacturers of America CEO Billy Tauzin said that "we've got a thick skin," adding that "we can handle" attacks. Tauzin also said that PhRMA has formed a task force to consider overhauls to industry marketing practices. He said, "We think some of the criticisms are valid and we ought to address them" (Wilde Mathews/Johnson, Wall Street Journal, 1/23).

Reprinted with kind permission from http://www.kaisernetwork.org. You can view the entire Kaiser Daily Health Policy Report, search the archives, or sign up for email delivery at http://www.kaisernetwork.org/dailyreports/healthpolicy. The Kaiser Daily Health Policy Report is published for kaisernetwork.org, a free service of The Henry J. Kaiser Family Foundation© 2005 Advisory Board Company and Kaiser Family Foundation. All rights reserved.




Customized Homepage Weekly Newsletters Daily News Alerts
Home About Us News Licensing Free Website Feeds Free Tools & Content Links Tell a Friend Accessibility Help / FAQ Article Submission Contact Us
Psychiatry Urology
Bipolar Diabetes Schizophrenia

add medical news today to your facebook

medical news gadget

Add to Google


developers
website gadget code
website news code
medical news rss feed links


MedReader RSS Reader

customize your homepage


These are the most read articles from this news category for the last 6 months:
Top Article Star
U.S. FDA Approves Requip® XL™, The First And Only Oral Once-daily Non-ergot Dopamine Agonist For Parkinson's Disease
15 Jun 2008
GlaxoSmithKline announced the approval of Requip® XL™(ropinirole extended-release tablets) in the U.S. for the treatment of the signs and symptoms of idiopathic Parkinson's disease...


When Your Cycle Becomes a Major Headache
When Your Cycle Becomes a Major Headache

Cathy's gets as many as 12 to 15 headaches a month and they are all associated with her menstrual cycle. Migraines like hers tend to last longer and be more severe than other migraines. Figuring out what was triggering her headaches helped Cathy and her doctor come up with a successful treatment plan.

more videos are available in our health videos section.